Abstract
C-peptide levels are in many ways a better measure of endogenous insulin secretion than peripheral insulin levels. C-peptide may be measured in either blood or urine. Perhaps the major advantage of measuring C-peptide levels is the ability to readily distinguish endogenous insulin levels in the presence of exogenous administration of insulin. Early C-peptide immunoassays were troubled by lack of sensitivity. This problem has now been overcome, and it is possible to measure C-peptide values down to extremely low levels. The clinical indications for C-peptide measurement include diagnosis of insulinoma and differentiation from factitious hypoglycemia, follow-up of pancreatectomy and evaluation of viability of islet cell transplants. Recently these indications have been dramatically expanded to permit evaluation of insulin dependence in maturity onset diabetes mellitus.
| Original language | English |
|---|---|
| Pages (from-to) | 105-113 |
| Number of pages | 9 |
| Journal | Acta Diabetologica Latina |
| Volume | 20 |
| Issue number | 2 |
| DOIs | |
| State | Published - Jun 1983 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Endocrinology
Cite this
The expanding clinical use of C-peptide radioimmunoassay. / Rendell, Marc.
In: Acta Diabetologica Latina, Vol. 20, No. 2, 06.1983, p. 105-113.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - The expanding clinical use of C-peptide radioimmunoassay
AU - Rendell, Marc
PY - 1983/6
Y1 - 1983/6
N2 - C-peptide levels are in many ways a better measure of endogenous insulin secretion than peripheral insulin levels. C-peptide may be measured in either blood or urine. Perhaps the major advantage of measuring C-peptide levels is the ability to readily distinguish endogenous insulin levels in the presence of exogenous administration of insulin. Early C-peptide immunoassays were troubled by lack of sensitivity. This problem has now been overcome, and it is possible to measure C-peptide values down to extremely low levels. The clinical indications for C-peptide measurement include diagnosis of insulinoma and differentiation from factitious hypoglycemia, follow-up of pancreatectomy and evaluation of viability of islet cell transplants. Recently these indications have been dramatically expanded to permit evaluation of insulin dependence in maturity onset diabetes mellitus.
AB - C-peptide levels are in many ways a better measure of endogenous insulin secretion than peripheral insulin levels. C-peptide may be measured in either blood or urine. Perhaps the major advantage of measuring C-peptide levels is the ability to readily distinguish endogenous insulin levels in the presence of exogenous administration of insulin. Early C-peptide immunoassays were troubled by lack of sensitivity. This problem has now been overcome, and it is possible to measure C-peptide values down to extremely low levels. The clinical indications for C-peptide measurement include diagnosis of insulinoma and differentiation from factitious hypoglycemia, follow-up of pancreatectomy and evaluation of viability of islet cell transplants. Recently these indications have been dramatically expanded to permit evaluation of insulin dependence in maturity onset diabetes mellitus.
UR - http://www.scopus.com/inward/record.url?scp=0020743754&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020743754&partnerID=8YFLogxK
U2 - 10.1007/BF02624911
DO - 10.1007/BF02624911
M3 - Review article
C2 - 6410638
AN - SCOPUS:0020743754
VL - 20
SP - 105
EP - 113
JO - Acta Diabetologica
JF - Acta Diabetologica
SN - 0940-5429
IS - 2
ER -